This review assessed the use of alteplase, given as an infusion or a bolus injection, and streptokinase for the treatment of pulmonary embolism. The authors concluded that firm recommendations as to which thrombolytic regimen is preferable cannot be drawn from the insufficient evidence found; further research is needed. This conclusion is appropriate given the data presented.
extraction.
The results were analysed on an intention-to-treat basis.
Methods of synthesis
How were the studies combined? Data from the RCTs were pooled using a random-effects model where heterogeneity existed. The pooled relative risk (RR), odds ratio (OR) and 95% confidence intervals (CIs) were calculated. In addition, outcome data for all cohorts assessing a particular drug were summed to give a percentage effect. A risk ratio between treatments was then estimated using a chi-squared test. The number-needed-to-harm (NNH) and number-needed-to-treat (NNT) were calculated where appropriate.
How were differences between studies investigated?
Heterogeneity was assessed using the chi-squared test. Sensitivity analyses were conducted based on severity of disease (massive PE versus nonmassive PE), methodological quality (score 3+ versus less than 3) and results from RCTs only.
Results of the review
Twenty-six studies were included: 16 RCTs (1,284 participants), 7 prospective studies (274 participants), 2 retrospective studies (153 participants) and 1 case study (6 participants).
Thrombolysis was not assessed for alteplase intravenous infusion versus bolus dose (2 RCTs). No significant differences in any other outcomes were observed between the two treatment groups.
There was no difference in all-cause mortality between alteplase infusion and streptokinase (RR 1.00, 95% CI: 0.07, 15.12, p=1.0; 2 RCTs). When an additional retrospective study was included, alteplase was associated with a trend towards greater incidence of major bleeding (RR 2.07, 95% CI: 0.8, 5.3, p=0.13).
Alteplase infusion was more effective than urokinase for thrombolysis (RR 1.32, 95% CI: 1.05, 1.67, p=0.02; 2 RCTs). The pooled analysis showed that all-cause mortality was similar for alteplase infusion compared with all other treatments combined (RR 1.34, 95% CI: 0.57, 3.14, p=0.7; 8 studies).
When data from cohorts on the same drug were combined and the results compared with those from different studies, alteplase infusion achieved thrombolysis in more cases than bolus dose alteplase (RR 1.95 95% CI: 1.19, 3.2, p=0.008; NNT 3). Streptokinase achieved thrombolysis in more cases than alteplase bolus dose (RR 2.48, 95% CI: 1.52, 4.03, p=0.0003) and alteplase infusion (RR 1.27, 95% CI: 1.09, 1.47, p=0.002; NNT=6). Alteplase infusion had a lower mortality from initial PE than either bolus dose alteplase or streptokinase (RR 0.16, 95% CI: 0.05, 0.59, p=0.005 and RR 0.13, 95% CI: 0.04, 0.46, p=0.001, respectively).
